Compare LARK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | RNA |
|---|---|---|
| Founded | 1885 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 222.5M |
| IPO Year | 2001 | 2025 |
| Metric | LARK | RNA |
|---|---|---|
| Price | $30.85 | $11.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 16.8K | ★ 229.2K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | $37.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $11.40 |
| 52 Week High | $32.39 | $73.06 |
| Indicator | LARK | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 36.53 |
| Support Level | $25.46 | $11.40 |
| Resistance Level | $30.80 | $14.05 |
| Average True Range (ATR) | 0.63 | 0.50 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 41.45 | 4.00 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.